By Denny Jacob
IGM Biosciences shares dived 69% in premarket trading a day after the company said it would halt development of two of its treatments.
Shares were trading around $1.94. The stock is up 1.5% on the year.
The biotechnology company said its decision to halt development would pertain to imvotamab and IGM-2644. It also cut its staff by 73% and is exploring internal options and strategic alternatives to maximize shareholder value while it looks to conserve cash.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 10, 2025 06:20 ET (11:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。